INVESTABOT
Equity Research
XNYS · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Medtronic (MDT) had 1 Form 144 pre-sale notice filed on 2026-07-08. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing ref…
Medtronic (MDT) had 1 Form 144 pre-sale notice filed on 2026-06-08. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Medtronic posted Q4 revenue of $9.8 billion, up 9.9% from $8.93 billion a year ago, beating its own implied guidance by 90 basis points. The results cap what the company calls its strongest annual revenue growth i…
TL;DR: Medtronic filed an officer change disclosure on May 18, 2026, but the available filing text does not identify the executive involved or the nature of the change. Without a named individual or stated role, the stra…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/3/2026 | Blomquist Denise L. | Chief Accounting Officer | GRANT | 2,337 | — | — |
| 8/3/2026 | Blomquist Denise L. | Chief Accounting Officer | GRANT | 1,366 | — | — |
| 8/3/2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 5,769 | — | — |
| 8/3/2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 14,421 | — | — |
| 8/3/2026 | Walter Matthew R. | SVP, Chief HR Officer | GRANT | 40,973 | — | — |
| 8/3/2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 6,923 | — | — |
| 8/3/2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 17,306 | — | — |
| 8/3/2026 | Thompson Kweli | EVP & President, Neuroscience | GRANT | 49,167 | — | — |
| 8/3/2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 6,346 | — | — |
| 8/3/2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 15,863 | — | — |
| 8/3/2026 | Quinn Michelle | EVP, GC and Secretary | GRANT | 45,070 | — | — |
| 8/3/2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 11,537 | — | — |
| 8/3/2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 28,842 | — | — |
| 8/3/2026 | Pieton Thierry | EVP & Chief Financial Officer | GRANT | 81,945 | — | — |
| 8/3/2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 10,960 | — | — |
| 8/3/2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 46,147 | — | — |
| 8/3/2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 27,400 | — | — |
| 8/3/2026 | Marinaro Michael | EVP, Pres MedSurg and Americas | GRANT | 77,848 | — | — |
| 8/3/2026 | KIIL HARRY SKIP | EVP & President Cardiovascular | GRANT | 9,230 | — | — |
| 8/3/2026 | KIIL HARRY SKIP | EVP & President Cardiovascular | GRANT | 23,074 | — | — |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 6/26/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 128,961,343 | $12,388,026,608 | — | 1/29/2026 |
| BlackRock | 120,537,878 | $11,578,868,646 | — | 2/12/2026 |
| BlackRock | 113,182,567 | $9,807,269,413 | -6.1% | 5/13/2026 |
| BlackRock | 114,020,787 | $8,919,846,142 | 0.7% | 8/7/2026 |
| BlackRock | 111,892,378 | $8,807,049,055 | — | 8/13/2024 |
| State Street | 61,660,158 | $5,966,780,403 | — | 2/13/2026 |
| State Street | 61,741,014 | $5,392,714,240 | 0.1% | 5/15/2026 |
| JP Morgan Chase | 53,616,694 | $5,150,419,786 | — | 2/11/2026 |
| State Street | 63,399,315 | $5,005,319,950 | 2.7% | 8/7/2026 |
| JP Morgan Chase | 51,058,541 | $4,377,759,541 | -4.8% | 5/13/2026 |
| JP Morgan Chase | 27,878,171 | $2,256,180,561 | -45.4% | 8/12/2026 |
| Morgan Stanley | 20,222,575 | $1,942,580,913 | — | 5/27/2026 |
| Morgan Stanley | 20,717,029 | $1,795,130,844 | 2.5% | 5/15/2026 |
| Morgan Stanley | 19,444,871 | $1,521,172,586 | -6.1% | 8/13/2026 |
| Goldman Sachs | 9,012,210 | $705,025,188 | 57.0% | 8/14/2026 |
| Citadel Advisors | 7,201,188 | $691,746,119 | — | 2/17/2026 |
| Citadel Advisors | 7,784,077 | $608,948,343 | 173.4% | 8/14/2026 |
| Goldman Sachs | 6,220,848 | $597,574,706 | — | 3/25/2026 |
| Goldman Sachs | 5,740,590 | $497,422,178 | -7.7% | 5/15/2026 |
| Millennium Management | 4,604,488 | $442,307,117 | — | 2/17/2026 |